Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $48.06, for a total transaction of $96,120.00. Following the completion of the transaction, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,578,372.26. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, January 21st, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $45.92, for a total transaction of $91,840.00.
• On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $49.32, for a total value of $98,640.00.
• On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.64, for a total value of $369,672.00.
• On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.16, for a total value of $366,168.00.
• On Tuesday, November 12th, Fady Ibraham Malik sold 6,342 shares of Cytokinetics stock. The shares were sold at an average price of $58.48, for a total transaction of $370,880.16.

Cytokinetics Stock Up 1.5 %

CYTK stock opened at $49.20 on Wednesday. The firm has a market cap of $5.81 billion, a PE ratio of -9.14 and a beta of 0.83. Cytokinetics, Incorporated has a 12 month low of $44.49 and a 12 month high of $81.36. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The firm has a 50 day simple moving average of $48.66 and a 200 day simple moving average of $52.57.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $1.21 million. During the same quarter last year, the firm earned ($1.35) EPS. The firm’s revenue was up 22.5% on a year-over-year basis. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CYTK shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a report on Tuesday, January 21st. Mizuho boosted their price target on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Tuesday, January 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.79.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors have recently bought and sold shares of CYTK. Impax Asset Management Group plc boosted its holdings in shares of Cytokinetics by 40.0% in the fourth quarter. Impax Asset Management Group plc now owns 175,000 shares of the biopharmaceutical company’s stock worth $8,232,000 after buying an additional 50,000 shares during the period. Centricity Wealth Management LLC acquired a new position in Cytokinetics in the 4th quarter worth approximately $29,000. Handelsbanken Fonder AB grew its position in Cytokinetics by 9.9% during the 4th quarter. Handelsbanken Fonder AB now owns 32,300 shares of the biopharmaceutical company’s stock worth $1,519,000 after purchasing an additional 2,900 shares in the last quarter. New York State Common Retirement Fund raised its stake in Cytokinetics by 2.9% during the 4th quarter. New York State Common Retirement Fund now owns 35,567 shares of the biopharmaceutical company’s stock valued at $1,673,000 after purchasing an additional 1,000 shares during the period. Finally, Peregrine Capital Management LLC lifted its holdings in shares of Cytokinetics by 6.7% in the fourth quarter. Peregrine Capital Management LLC now owns 150,343 shares of the biopharmaceutical company’s stock valued at $7,072,000 after purchasing an additional 9,432 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.